Product Name: AMPKa2 (349-365)
Product Number: PE-01BCD99
Size: 200 µg      Price:58.00
1 mg      $US115.00
5 mg      252.00
Peptide Name: AMPKa2 (349-365)

Product Use: Services as a blocking peptide for use with the AMPKa2-AKCD rabbit polyclonal antibody (Cat. No.: AB-NK260-1) that is also available from Kinexus. The peptide sequence is located after the kinase catalytic domain in region not conserved with AMPKa1.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: CGSFMDDSAMHIPPGLKP

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1902.2 Da

Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: AMPKa2 pan-specific antibody (Cat. No.: AB-NK260-1)

Scientific Background: AMPKa2 (PRKAA2) is a protein-serine/threonine kinase of the CAMK group and CAMKL family. It is the catalytic subunit of AMP-activated protein kinase (AMPK),which is an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. It also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton. Binding of AMP results in allosteric activation, inducing phosphorylation on T172 by STK11 in complex with STE20-related adapter-alpha (STRAD alpha) pseudo kinase and CAB39.It is also activated by phosphorylation by CAMKK2 triggered by a rise in intracellular calcium ions, without detectable changes in the AMP/ATP ratio. Defects in PRKAA2 are linked to Peutz-Jeghers Syndrome, which is a relatively rare autosomal dominant disease where benign polyps develop on the GI tract.